A podcast series from Quest Diagnostics

A podcast series from Quest Diagnostics header image 1

Dangerous Drug Combinations

quest-ep4-twitter.png

Welcome to the Quest Diagnostics “topics in drug testing” podcast. Today’s episode is with Quest Diagnostics Senior Medical Advisor Dr Jeff Gudin and Medical Science Liaison Dr Jack Kain. Drs Gudin and Kain will be discussing “dangerous drug combinations.”

The podcast will cover:

  • What are dangerous drug combinations
  • What practitioners and the public need to know about them
  • How the drug combinations can work together to lead to side effects
    • Certain combinations predispose people to a greater risk of overdose and death
    • Can affect drug levels, creating a pharmacokinetic drug–drug interaction
    • May result in excessive sedation
  • How drug testing can help
    • A tool to identify dangerous drug combinations
    • Identifies metabolites unique to a substance

You may download the PDF version of this presentation here>>

To learn more, please visit QuestDrugMonitoring.com for information on our Drug Monitoring Test Directory and offerings, as well as educational resources and insights from our team of toxicology experts. At Quest Diagnostics, we are committed to providing you results and insights to support your clinical decisions.

Screening for alcohol use in pain management and primary care: it’s about time

quest-ep3-tweet.png

Welcome to the Quest Diagnostics “Topics in drug testing” podcast. Today’s episode is with Quest Diagnostics Senior Medical Advisor Dr Jeff Gudin and Medical Science Liaison Dr Jack Kain. Drs Gudin and Kain will be discussing “Screening for alcohol use in pain management and primary care.”

The podcast will cover the importance of alcohol testing in order to:

  • Understand drug and alcohol misuse and abuse

    • Share prevalence rates of alcohol use and misuse, and alcohol use disorders
    • Provide information on alcohol use, and concomitant use with opioids and benzodiazepines
  • Screening guidelines
    • Tools and types of tests
  • Testing for alcohol
    • Breathalyzer
    • Advances in testing
    • Biomarkers
    • Other considerations
    • Quest Diagnostics approach

You may download the PDF version of this presentation here>>

To learn more, please visit QuestDrugMonitoring.com for information on our Drug Monitoring Test Directory and offerings, as well as educational resources and insights from our team of toxicology experts. At Quest Diagnostics, we are committed to providing you results and insights to support your clinical decisions.

Patients with substance use disorders in medication-assisted treatment (MAT)

ep2-quest-tweet.png

Welcome to the Quest Diagnostics “topics in drug testing” podcast. Today’s episode is with Quest Diagnostics Senior Medical Advisor, Dr Jeff Gudin, and Medical Science Liaison, Dr Jack Kain. They will be discussing drug testing for patients with substance use disorders in medication-assisted treatment (MAT).

In today’s episode, some of the points that will be covered include:

  • What is medication-assisted treatment?
  • What are the goals of the treatment program?
  • The medications used in the treatment program 
  • Drug testing during MAT
    • Purpose of drug testing
    • Types of drug testing
      • Specimen collection
      • Specimen validity
    • Test confirmation

You may download the PDF version of this presentation here >

To learn more, please visit QuestDrugMonitoring.com for information on our Drug Monitoring Test Directory and offerings, as well as educational resources and insights from our team of toxicology experts. At Quest Diagnostics, we are committed to providing you results and insights to support your clinical decisions.

Drug testing your patients for marijuana

1200x675_quest-ep1-thc.png

Welcome to the Quest Diagnostics “topics in drug testing” podcast. Today’s episode is with Quest Diagnostics Senior Medical Advisor, Dr Jeff Gudin, and Medical Science Liaison, Dr Jack Kain. They will be discussing drug testing your patients for marijuana.

Today, we’ll be talking about marijuana and marijuana-based products in order to:

  • Understand drug testing for marijuana, and why it’s important
  • Give some general recommendations for therapeutic drug monitoring for marijuana in patients with chronic pain using controlled substances
    • For example, at a minimum such patients should be tested before opioid therapy begins, again within 1 to 3 months, and randomly over the next 12 months, and more frequently if there are unexpected results, or there are complaints or behavior changes in the patient

 You may download the PDF version of this presentation here >

To learn more, please visit QuestDrugMonitoring.com for information on our Drug Monitoring Test Directory and offerings, as well as educational resources and insights from our team of toxicology experts. At Quest Diagnostics, we are committed to providing you results and insights to support your clinical decisions.